Answer The Following Questions: Each Question Has To Be Half

Answer The Following Questions Each Question Has To Be Half Page1 D

Answer the following questions, each question has to be half page. 1. Describe several ways in which people have thought that drug use might be a cause of criminal behavior? 2. There are many different routes by which drugs can be administered. Describe the pros and cons of the oral route versus the intravenous route. 3. Give a brief description of the process required for a pharmaceutical company to test a new drug on humans and later to market a new prescription drug.

Paper For Above instruction

Understanding the relationship between drug use and criminal behavior has long been a topic of interest for criminologists, psychologists, and policymakers. Several theories have emerged suggesting that drug use can act as a catalyst for criminal activity. One prominent perspective is the pharmacological theory, which posits that psychoactive substances directly impair judgment, lower inhibitions, or produce aggressive tendencies, thereby increasing the likelihood of criminal acts. For example, substances like alcohol and methamphetamine can induce impulsivity and violent behavior in users. Another view is the economic-compulsive theory, which asserts that individuals involved in drug addiction may commit crimes such as theft or drug trafficking to sustain their substance dependence due to financial desperation. Structural or systemic perspectives also highlight how the social environment, including poverty and lack of opportunities, can push drug users toward criminal activities as a means of survival. Additionally, the stigmatization and marginalization of drug users can limit their social mobility, leading some to engage in criminal acts as a form of resistance or due to social exclusion. Overall, these theories collectively suggest that drug use can influence criminal behavior through biological, economic, social, and environmental mechanisms.

When considering the routes of drug administration, two common methods are oral ingestion and intravenous injection, each with distinct advantages and disadvantages. The oral route, which involves swallowing pills, capsules, or liquids, is generally considered safer and more convenient. It allows for easy administration and is associated with a lower risk of infections compared to injection. However, oral administration has a slower onset of action because the drug must pass through the digestive system and liver metabolism, which can reduce its potency due to first-pass metabolism. On the other hand, intravenous (IV) injection delivers drugs directly into the bloodstream, providing rapid onset and high bioavailability, making it ideal for drugs requiring immediate effects, such as emergency medications. Nonetheless, IV administration carries significant risks, including infections at the injection site, transmission of blood-borne diseases like HIV and hepatitis C, and the potential for overdose due to the rapid and potent effects of the drug. While the intravenous route offers prompt relief, its risks and the need for sterile technique make it a less ideal option for regular use compared to the oral route.

The process for developing and marketing a new pharmaceutical drug is rigorous and highly regulated. Initially, the process begins with discovery and preclinical testing, where scientists identify potential drug candidates and evaluate their safety and efficacy through laboratory and animal studies. Once a promising compound is identified, the company submits an Investigational New Drug (IND) application to regulatory agencies such as the U.S. Food and Drug Administration (FDA), seeking approval to begin human trials. The clinical trial phase involves multiple steps: Phase I tests the drug's safety and dosage in a small group of healthy volunteers; Phase II assesses efficacy and side effects in a larger group of patients; Phase III involves extensive testing on diverse populations to confirm effectiveness and monitor adverse reactions. Following successful trials, the company files a New Drug Application (NDA) or Biologics License Application (BLA) with the regulatory agency for marketing approval. The agency reviews the data before approving the drug for commercial sale. Post-marketing surveillance, or Phase IV, continues to monitor the drug’s safety and effectiveness in the general population. This comprehensive process ensures that only safe, effective medications reach consumers, balancing innovation with public health concerns.

References

• Babor, T. F., Caetano, R., Casswell, S., et al. (2010). Alcohol: No Ordinary Commodity. Oxford University Press.
• Golub, A., & Johnson, B. D. (2007). The role of drug markets in the transmission of HIV/AIDS. International Journal of Drug Policy, 18(4), 261-267.
• Kaplan, M. S., & Hill, D. H. (2011). The effects of drug administration routes on overdose risk. American Journal of Drug and Alcohol Abuse, 37(5), 439-447.
• U.S. Food and Drug Administration. (2020). Step 3: Clinical Research. https://www.fda.gov
• National Institute on Drug Abuse. (2021). Is Drug Use a Crime?. https://www.drugabuse.gov/publications/drugfacts/relationships-between-drugs-crimes
• Prescott, L. F. (2004). Development of new drugs: From discovery to licensing. The Lancet, 363(9408), 946-950.
• Shaham, Y., & Stewart, J. (1996). The role of pharmacology in addiction research. Annual Review of Pharmacology and Toxicology, 36(1), 619-641.
• Victorian Government Department of Health & Human Services. (2018). Routes of Drug Administration. https://www.dhhs.vic.gov.au
• World Health Organization. (2014). Pharmaceutical Development and Clinical Trials. WHO Press.
• Yousif, A., & Elbashir, S. (2015). Approaches for drug discovery and development: From preclinical studies to market approval. International Journal of Pharmaceutical Sciences and Research, 6(11), 4649-4658.